Xi'an International Medical Center Hospital, Xi'an, Shaanxi Province 710100, China.
Comput Math Methods Med. 2022 Oct 26;2022:1072218. doi: 10.1155/2022/1072218. eCollection 2022.
To compare and analyze the clinical characteristics of invasive micropapillary carcinoma (IMPC) of the breast (IMPC-B) and invasive ductal carcinoma (IDC) of the breast (IDC-B) and establish a prognostic model of IMPC-B.
We retrospectively analyzed data for patients diagnosed with breast cancer in the Surveillance, Epidemiology, and End Results (SEER) database between 2010 and 2018 and screened 581 patients with IMPC and 1325 patients with IDC. We compared age, race, laterality, tumor site, histological grade, type of surgery, radiation, chemotherapy, whether the first primary tumor, T stage, N stage, M stage, and molecular type between IMPC-B and IDC-B and draw survival curves of IMPC-B and IDC-B. The relationship between clinical factors and prognosis was investigated by univariate analysis using the Log-rank test and multivariate analysis of the Cox proportional hazards regression model. A risk scoring model was constructed based on independent risk factors to distinguish high-risk and low-risk patients; in addition, a nomogram was created to predict patient survival.
There were differences between the two groups in the age of onset, race, tumor site, histological grade, type of surgery, N stage, and molecular type ( < 0.05). Overall survival was decreased in IMPC-B compared with IDC-B ( < 0.05). The prognosis of IMPC-B was significantly correlated with histological grade, whether the first primary tumor, type of surgery, radiotherapy, chemotherapy, T stage, and N stage. Based on the relationship between the above factors and overall survival prognosis, the risk score model we constructed can effectively distinguish high-risk and low-risk patients ( < 0.05). The established nomogram had better performance in predicting survival in patients with IMPC-B (C - index = 0.78).
IMPC-B has a worse prognosis than IDC-B, with earlier age of onset, higher histological grade, and later N stage, and luminal breast cancer is the main type. The nomogram can well predict the prognosis of patients with IMPC-B, which has a high clinical reference value and provides a scientific basis for clinical treatment.
比较分析乳腺浸润性微乳头状癌（IMPC-B）与乳腺浸润性导管癌（IDC-B）的临床特征，并建立 IMPC-B 的预后模型。
回顾性分析 2010 年至 2018 年 SEER 数据库中诊断为乳腺癌的患者数据，筛选出 581 例 IMPC 患者和 1325 例 IDC 患者。比较 IMPC-B 与 IDC-B 的年龄、种族、侧别、肿瘤部位、组织学分级、手术类型、放疗、化疗、是否为首发肿瘤、T 分期、N 分期、M 分期和分子类型，并绘制 IMPC-B 和 IDC-B 的生存曲线。采用 Log-rank 检验进行单因素分析，Cox 比例风险回归模型进行多因素分析，探讨临床因素与预后的关系。基于独立危险因素构建风险评分模型，区分高风险和低风险患者；此外，创建一个列线图来预测患者的生存情况。
两组患者在发病年龄、种族、肿瘤部位、组织学分级、手术类型、N 分期和分子类型方面存在差异（ < 0.05）。与 IDC-B 相比，IMPC-B 的总生存率降低（ < 0.05）。IMPC-B 的预后与组织学分级、是否为首发肿瘤、手术类型、放疗、化疗、T 分期和 N 分期显著相关。基于上述因素与总生存预后的关系，我们构建的风险评分模型可以有效区分高风险和低风险患者（ < 0.05）。建立的列线图在预测 IMPC-B 患者的生存方面具有更好的性能（C - 指数= 0.78）。
IMPC-B 较 IDC-B 预后更差，发病年龄更早，组织学分级更高，N 分期更晚，以腔面型乳腺癌为主。该列线图能较好地预测 IMPC-B 患者的预后，具有较高的临床参考价值，可为临床治疗提供科学依据。
